Related Experiment Video
Updated: Nov 19, 2025
Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy
Published on: October 28, 2022
Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Brain Injury
José Martínez-Orgado1, María Villa2, Aarón Del Pozo2
1Division of Neonatology, Hospital Clínico San Carlos - IdISSC, Madrid, Spain.
Insights
Cannabidiol (CBD) shows neuroprotective effects against Hypoxic-Ischemic Brain Injury (HIBI) in preclinical models. This promising treatment protects brain cells and myelin, offering hope for newborns with HIBI.
Area of Science:
- Neuroscience
- Neonatal Medicine
- Pharmacology
Background:
- Hypoxic-Ischemic Brain Injury (HIBI) causes millions of neonatal deaths and long-term disabilities annually.
- Current treatments like therapeutic hypothermia have limited efficacy for many newborns.
- HIBI pathophysiology involves excitotoxicity, inflammation, and oxidative stress.
Purpose of the Study:
- To evaluate the neuroprotective potential of Cannabidiol (CBD) in preclinical models of neonatal HIBI.
- To investigate the mechanisms underlying CBD's effects on brain injury.
- To assess CBD's safety and efficacy for HIBI management.
Main Methods:
- Preclinical studies in newborn pigs and rodents subjected to hypoxic-ischemic insults.
- Administration of Cannabidiol (CBD) post-insult.
- Assessment of neuroprotection using functional, neuroimaging, histologic, and biochemical analyses.
Main Results:
- CBD demonstrated significant short- and long-term neuroprotective effects in HIBI models.
- CBD modulated excitotoxicity, inflammation, and oxidative stress, key HIBI components.
- CBD protected neuronal and glial cells and preserved myelinogenesis.
Conclusions:
- Cannabidiol (CBD) is a safe and effective neuroprotective agent for neonatal Hypoxic-Ischemic Brain Injury (HIBI).
- CBD's broad therapeutic window and parenteral administration make it a viable clinical candidate.
- Clinical trials are underway to confirm CBD's efficacy in human neonates.
Abstract:
Each year, more than two million babies die or evolve to permanent invalidating sequelae worldwide because of Hypoxic-Ischemic Brain Injury (HIBI). There is no current treatment for that condition except for therapeutic hypothermia, which benefits only a select group of newborns. Preclinical studies offer solid evidence of the neuroprotective effects of Cannabidiol (CBD) when administered after diffuse or focal HI insults to newborn pigs and rodents. Such effects are observable in the short and long term as demonstrated by functional, neuroimaging, histologic and biochemical studies, and are related to the modulation of excitotoxicity, inflammation and oxidative stress-the major components of HIBI pathophysiology. CBD protects neuronal and glial cells, with a remarkable effect on preserving normal myelinogenesis. From a translational point of view CBD is a valuable tool for HIBI management since it is safe and effective. It is administered by the parenteral route a posteriori with a broad therapeutic time window. Those findings consolidate CBD as a promising treatment for neonatal HIBI, which is to be demonstrated in clinical trials currently in progress.
